The FY2018 President’s Budget for the Department of Health and Human Services (HHS) has significant implications for medicine, public health, and science.
The bill provides a $2 billion increase in funding for the National Institutes of Health (NIH) to support important research.
The Trump administration lags behind its recent predecessors in making nominations for key government management positions.
At its all-time high in 1964, federal R&D spending amounted to almost 2 percent of GDP. Today, it’s just 0.7 percent—the lowest level in over 50 years.
This agreement demonstrates the best and worst of this Congress. On the positive side, Congress is again forging consensus on contentious policy issues.
There is growing recognition that prevention holds vast potential to improve health, while also reducing national spending on health care.
Americans spend twice as much on health care as citizens of other developed nations, yet we have shorter life expectancies and higher rates of infant mortality and diabetes.
The legislation affords tremendous opportunity for providing hope for patients and accelerated progress on research, new medicines and treatments.